Collagenase-3 (MMP-13) expression in cutaneous malignant melanoma

• Published in: The International journal of biological markers 2005-10, Vol.20 (4), p.242-248
• Main Authors: CORTE, M. D, GONZALEZ, L. O, CORTE, M. G, QUINTELA, I, PIDAL, I, BONGERA, M, VIZOSO, F
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Analytical, structural and metabolic biochemistry; Biological and medical sciences; Child; Collagenases - metabolism; Disease-Free Survival; Female; Fundamental and applied biological sciences. Psychology; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Investigative techniques, diagnostic techniques (general aspects); Male; Matrix Metalloproteinase 13; Medical sciences; Melanoma - enzymology; Melanoma - metabolism; Melanoma - pathology; Middle Aged; Skin Neoplasms - enzymology; Skin Neoplasms - metabolism; Skin Neoplasms - pathology
• ISSN: 0393-6155; 1724-6008
• DOI: 10.1177/172460080502000407

Matrix metalloproteases (MMPs), enzymes with the ability to degrade the extracellular matrix, play an important role in tissue invasion by cutaneous malignant melanoma (CMM). One specific MMP, collagenase-3 (MMP-13), is thought to have a key function in the activation of MMP. To evaluate the expression of MMP-13 in CMM and assess its possible relationship to clinical and pathological parameters. MMP-13 expression was analyzed in 51 paraffin-embedded tumor samples from patients with invasive CMM, ten samples from in situ melanomas, and in eight samples from benign lesions (three dermal melanocytic nevi, three compound melanocytic nevi and two atypical melanocytic nevi) using immunohistochemical techniques. The median follow-up period in patients with invasive CMM was 50 months. Benign lesions were consistently negative for MMP-13, whereas three of the ten in situ melanomas (30%) and 23 of the 51 invasive CMMs (45%) showed positive immunostaining for MMP-13. The percentage of MMP-13-positive tumors correlated significantly and positively with the mitotic index (p=0.002) in invasive CMM. However, our results did not show any significant association between tumoral MMP-13 expression and relapse-free survival in patients with invasive CMM. MMP-13 appears to be a factor associated with tumor aggressiveness in CMM. It seems to eliminate an important barrier not only against tumoral invasion but also against proliferation.